BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37952807)

  • 1. Lung Cancer Screening in Clinical Practice: A 5-Year Review of Frequency and Predictors of Lung Cancer in the Screened Population.
    Lafata KJ; Read C; Tong BC; Akinyemiju T; Wang C; Cerullo M; Tailor TD
    J Am Coll Radiol; 2024 May; 21(5):767-777. PubMed ID: 37952807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Lung Cancer CT Screening Performance, Smoking Behavior, and Adherence to Recommendations: Lung-RADS Category and Smoking Status Predict Adherence.
    Barbosa EJM; Yang R; Hershman M
    AJR Am J Roentgenol; 2021 Apr; 216(4):919-926. PubMed ID: 32755178
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes From More Than 1 Million People Screened for Lung Cancer With Low-Dose CT Imaging.
    Silvestri GA; Goldman L; Tanner NT; Burleson J; Gould M; Kazerooni EA; Mazzone PJ; Rivera MP; Doria-Rose VP; Rosenthal LS; Simanowith M; Smith RA; Fedewa S
    Chest; 2023 Jul; 164(1):241-251. PubMed ID: 36773935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.
    Silva M; Milanese G; Sestini S; Sabia F; Jacobs C; van Ginneken B; Prokop M; Schaefer-Prokop CM; Marchianò A; Sverzellati N; Pastorino U
    Eur Radiol; 2021 Apr; 31(4):1956-1968. PubMed ID: 32997182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice.
    Mendoza DP; Petranovic M; Som A; Wu MY; Park EY; Zhang EW; Archer JM; McDermott S; Khandekar M; Lanuti M; Gainor JF; Lennes IT; Shepard JO; Digumarthy SR
    AJR Am J Roentgenol; 2022 Jul; 219(1):55-65. PubMed ID: 35080453
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT.
    Zhang EW; Shepard JO; Kuo A; Chintanapakdee W; Keane F; Gainor JF; Mino-Kenudson M; Lanuti M; Lennes IT; Digumarthy SR
    Cancer Epidemiol Biomarkers Prev; 2021 Aug; 30(8):1472-1479. PubMed ID: 34108138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Diagnostic CT and Patient Retention in a Lung Cancer Screening Program.
    Byrne SC; Hammer MM
    J Am Coll Radiol; 2022 Jan; 19(1 Pt A):47-52. PubMed ID: 34752759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delays in Recommended Follow-Up after Positive Findings in Lung Cancer Screening.
    Ahmed A; Hippe DS; Snidarich M; Crothers K; Triplette M
    Ann Am Thorac Soc; 2023 Aug; 20(8):1175-1181. PubMed ID: 36973008
    [No Abstract]   [Full Text] [Related]  

  • 9. Lung Cancer Screening at a Military Treatment Facility: A Retrospective Review.
    White LJ; Kaur A; Lapel RT; E Boswell G; Luceri RE; Parrish JS; Seda G
    Mil Med; 2020 Jun; 185(5-6):e864-e869. PubMed ID: 31925432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HUNCHEST-II contributes to a shift to earlier-stage lung cancer detection: final results of a nationwide screening program.
    Kerpel-Fronius A; Megyesfalvi Z; Markóczy Z; Solymosi D; Csányi P; Tisza J; Kecskés A; Baranyi B; Csánky E; Dóka A; Gálffy G; Göcző K; Győry C; Horváth Z; Juhász T; Kállai Á; Kincses ZT; Király Z; Király-Incze E; Kostyál L; Kovács A; Kovács A; Kuczkó É; Makra Z; Maurovich Horvát P; Merth G; Moldoványi I; Müller V; Pápai-Székely Z; Papp D; Polgár C; Rózsa P; Sárosi V; Szalai Z; Székely A; Szuhács M; Tárnoki D; Tavaszi G; Turóczi-Kirizs R; Tóth L; Urbán L; Vaskó A; Vigh É; Dome B; Bogos K
    Eur Radiol; 2024 May; 34(5):3462-3470. PubMed ID: 37921926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of ACR Lung-RADS in a clinical CT lung screening program.
    McKee BJ; Regis SM; McKee AB; Flacke S; Wald C
    J Am Coll Radiol; 2015 Mar; 12(3):273-6. PubMed ID: 25176499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial Disparities in Adherence to Annual Lung Cancer Screening and Recommended Follow-Up Care: A Multicenter Cohort Study.
    Kim RY; Rendle KA; Mitra N; Saia CA; Neslund-Dudas C; Greenlee RT; Burnett-Hartman AN; Honda SA; Simoff MJ; Schapira MM; Croswell JM; Meza R; Ritzwoller DP; Vachani A
    Ann Am Thorac Soc; 2022 Sep; 19(9):1561-1569. PubMed ID: 35167781
    [No Abstract]   [Full Text] [Related]  

  • 14. The 10 Pillars of Lung Cancer Screening: Rationale and Logistics of a Lung Cancer Screening Program.
    Fintelmann FJ; Bernheim A; Digumarthy SR; Lennes IT; Kalra MK; Gilman MD; Sharma A; Flores EJ; Muse VV; Shepard JA
    Radiographics; 2015; 35(7):1893-908. PubMed ID: 26495797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Identification of Lung Cancer Screening Follow-Up Recommendations and the Association with Adherence.
    Triplette M; Wenger DS; Shahrir S; Kross EK; Kava C; Phipps A; Hawes SE; Cole A; Snidarich M; Crothers K
    Ann Am Thorac Soc; 2022 May; 19(5):799-806. PubMed ID: 34727513
    [No Abstract]   [Full Text] [Related]  

  • 16. Management and Outcomes of Suspected Infectious and Inflammatory Lung Abnormalities Identified on Lung Cancer Screening CT.
    Mendoza DP; Chintanapakdee W; Zhang EW; Gilman MD; Lennes IT; Frank AJ; Shepard JO; Digumarthy SR
    AJR Am J Roentgenol; 2021 Nov; 217(5):1083-1092. PubMed ID: 33377416
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors Associated With Nonadherence to Lung Cancer Screening Across Multiple Screening Time Points.
    Lin Y; Liang LJ; Ding R; Prosper AE; Aberle DR; Hsu W
    JAMA Netw Open; 2023 May; 6(5):e2315250. PubMed ID: 37227725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the Vancouver Risk Calculator Compared with Lung-RADS in an Urban, Diverse Clinical Lung Cancer Screening Cohort.
    Kessler A; Peng R; Mardakhaev E; Haramati LB; White CS
    Radiol Imaging Cancer; 2020 Mar; 2(2):e190021. PubMed ID: 33778703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Downstream Procedures on Lung Cancer Screening Adherence.
    Tailor TD; Bell S; Carlos RC
    J Am Coll Radiol; 2023 Oct; 20(10):969-978. PubMed ID: 37586471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung-RADS Version 1.1: Challenges and a Look Ahead, From the
    Chelala L; Hossain R; Kazerooni EA; Christensen JD; Dyer DS; White CS
    AJR Am J Roentgenol; 2021 Jun; 216(6):1411-1422. PubMed ID: 33470834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.